updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim apr
price data apr
rate updat apr
currenc amount express
valuat growth profit
methodolog valu compani
thank shift manag abl focu
structur competit advantag improv balanc sheet
judici step differ market even
vagari product cycl control roughli
 digit mammographi market lead way first
mammographi adopt slow still
opportun growth smaller hospit oversea
importantli clinic data still give edg
pricey gen-prob acquisit also hold top
posit host diagnost test focus women health
run sole proprietari instrument think
done good job capit prolifer low-
midvolum lab panther equip gain
traction expand recur revenu base
howev must contend secular competit
interv
lengthen reduc pap smear volum forc
preserv market share hpv price
also fallen dramat seek maintain share
addit siemen enter
mammographi market add new element competit
given ge entrench select hospit abil bundl
extens menu capit equip
materi think abl navig
pressur center medicar medicaid servic
establish reimburs mammographi appear
lucr firm custom base help
adopt believ first-mov advantag
mammographi wide instal base strong trial valid
provid firm foot market recent addit
cynosur provid entre aesthet market less
reliant reimburs broaden portfolio
translat even growth along line
larger med-tech firm enjoy
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
manufactur proprietari product healthcar need
women compani oper four segment diagnost sale
breast health surgic skelet health
compani tradit focus breast health recent acquisit
gen-prob put much greater emphasi commerci diagnost
unit state account largest portion firm revenu
follow europ asia headquart
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
met expect top bottom line
hold steadi fair valu estim firm
done good job put right peopl place
restructur group dedic intern busi
execut improv geographi robust
intern contribut put diagnost breast
health growth back track consid holog
underpenetr intern segment expect
effort continu bear fruit support
revenu growth project
sale rel small surgic product
segment disappoint optimist
novasur buck increas competit slow market
growth whole hearten see healthi
growth key segment molecular diagnost
breast health saw quarterli growth
respect constant currenc think strength
advantag siemen
help placement
new
system
perform legaci cynosur remain soft
larg reflect challeng rebuild
salesforc support unit opinion
optimist line-up new product includ
tempsur envi stimul collagen gener reduc
wrinkl cellulit moreov favor macroeconom
condit worker see wage increas
present environ conduc aesthet product
luck see growth segment
pick next quarter
valuat growth profit may
moder increas fair valu estim
per share reflect time valu money
addit cynosur divestitur blood screen
busi well slightli optimist expect
intern growth
holog abil integr cynosur maintain
gradual growth digit mammographi upgrad
cycl launch new diagnost test key
factor valuat continu think firm
well posit roll-out panther instrument
widen stream recur test revenu
also believ entri viral-load test
boost appeal assay menu help compens
sluggish hpv price intern side
anticip near-term expans europ slow
entri emerg market play greater role
perform europ proxi also anticip
also forecast modest top-lin gain surgic skelet
health taken togeth along addit cynosur
project compound-annual-growth-rate explicit forecast
believ price pressur persist across
product forecast gross margin rang
firm increas recur
revenu higher-margin test servic expans
instal base mammographi equip
panther unit also translat slight improv
oper margin despit greater invest sell
gener administr expens research
uncertainti surround liquid-bas
cytolog revenu present overhang believ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
busi segment hinder growth particularli
diagnost assum slowdown europ emerg
market tighten hospit budget stringent
requir approv regulatori agenc
bear-cas fair valu estim per share reflect
compound annual growth total revenu
billion fiscal
believ dug narrow econom moat base
switch cost intellectu properti
surround breast health diagnost platform
pioneer first fda-approv mammographi
platform continu expand instal
base unit mammographi equip
typic big-ticket purchas hospit
radiolog clinic price tag per digit
unit per instal time
retrain system reorgan work flow mean
custom littl incent switch platform
furthermor consider less expens
holog custom upgrad equip rather
switch compet system sizabl instal
base firm also reap benefit five-year servic
contract annual cost purchas
price option instal base
fall contract
addit lengthi fda approv process
sophist technolog tall barrier deter
new market entrant though gener electr
siemen receiv fda approv system
add new level competit could appli
price pressur think grow bodi clinic data
geniu system help establish superior
mind clinician two year
new competit yet seen soft
averag sell price
firm sale mix capit equip consum
servic revenu translat averag cash flow volatil
warrant medium uncertainti rate base-cas
fair valu estim depend larg firm abil
maintain instal base diagnost instrument
expand test menu medic commun
accept breast tomosynthesi also key variabl
underli assumpt
bull-cas scenario assum edg
market share liquid-bas
pap smear volum reset firm maintain
healthi pace panther instal could also captur
greater share test sexual transmit diseas
scenario also assum breast tomosynthesi gain
better traction proven efficaci cost-effect
recent establish public reimburs
acceler placement faster clip
bull-cas fair valu estim per share reflect
compound annual growth rate total revenu
billion fiscal
bear case competit price pressur across
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
platform remain solid size
compani digit instal base give us confid
maintain momentum upgrad despit new
entrant market remain competit
need maintain technolog edg equip
upgrad new product introduct appeal
within diagnost firm face consider headwind
pap smear market secular declin
recommend test interv extend one mani
five year women hpv test also come
heavi price pressur volum leader seek
maintain market share need continu
expand menu test appeal commerci
lab enhanc front-end autom capabl
instrument
overal feel firm well posit
front firm enter viral-load test hiv hep
 area billion market allianc quest could
also open menu expans opportun firm
co-develop promot new diagnost solut
acquir gen-prob diagnost
divis also leverag high switch cost
surround proprietari instrument test
run ad thinprep lead share
liquid-bas pap market acquisit dramat
hpv
chlamydia gonorrhea trichomona blood screen
lab commit firm autom equip
streamlin oper run compani test
consolid workflow fewer platform addit
time requir train lab technician adjust work flow
steep switch cost built around instrument
price tag built per-reag cost
addit cynosur provid
sizeabl footprint aesthet market anticip
could bolster moat intellectu properti
surround cynosur variou laser may
opportun build brand segment
direct-to-consum commun allergan
think holog remain segment surgic
skelet health moat firm hysteroscop
surgic product myosur led pocket success
strong cash flow howev lower-cost altern
put pressur novasur product advers
macroeconom condit result mix skelet
result nevertheless believ breast health
diagnost segment
believ moat trend stabl within breast
health competit ramp ge
siemen receiv regulatori approv rival
enjoy strong brand name access greater resourc
technolog innov nevertheless uptak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
first market fda-approv
mammographi platform unit state give
consider head start gener electr
siemen
control lion share liquid-
base pap market gen-prob acquisit
catapult firm number-on posit
test chlamydia gonorrhea blood screen
ogovern reimburs mammographi
appear lucr custom base
acceler system placement
owith mammographi screen guidelin flux
potenti drop-off mammogram volum could hurt
owhil geograph expans effort way
rel littl intern exposur
leav heavi tax burden
odespit full pipelin best effort high
degre clinic regulatori risk surround
product regulatori path approv
expens time-consum fruitless process
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
took consider leverag billion
acquisit gen-prob decemb
owe billion debt held million
stephen macmillan lead firm note
prefer oper firm substanti less
leverag balanc sheet held begin
tenur net debt/ebitda
macmillan balanc sheet typic held cash
debt sinc join firm new
manag team activ de-lever holog
set exceed goal time net debt/ebitda
end fiscal
sale influenc capit spend pattern
hospit clinic could advers affect
prolong econom downturn effect
macroeconom downturn could exacerb
consum forgo cosmet laser treatment
interest tighten financi belt diagnost
market particip
also
competit firm sale could suffer
stabil pap smear market take longer
anticip furthermor signific exposur
regulatori risk particularli within secur reimburs
fda approv new product introduct also
approxim sale come intern
market currenc headwind could neg impact
top- bottom-lin perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
award holog standard mark stewardship
stephen macmillan step ceo late
macmillan formerli serv ceo
corpor hold
year oper experi healthcar
industri overal think macmillan well suit
job follow effect tenur execut
number success direct make sound
acquisit experi benefit
oper strategi macmillan also track record
gener free cash flow manag debt holog
benefit firm deleverag balanc
sheet follow gen-prob acquisit put holog
favor posit make acquisit broaden
firm footprint
complaint holog acquisit
come hefti price revalu goodwil
led billion impair charg relat
third wave gen-prob reflect
current manag team recogn earlier
 decis previou manag team
cost sharehold macmillan helm
confid deploy cash prudent go
repres date owner name posit common share held report holder issuer
va collegeamerica growth fund america
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
report intern growth
report fourth-quart fiscal earn line
expect maintain fair
valu estim narrow moat rate quarter
character growth diagnost intern
busi holog cynosur woe continu
project fiscal top-lin growth put us modestli
midpoint manag initi outlook mid-
pleas see restructur holog
intern busi grew constant
currenc pay firm year ago holog
intern busi struggl leader express
abroad busi would work progress
quarter clear chang manag
revamp salesforc begun bear fruit meaning
contribut growth overal busi
struggl declin roughli year year
reflect fallout consider sale rep turnov
expect declin due season
manag turnov environment impact due
recent hurrican result still weaker
expect manag quickli instal kevin thornal
presid cynosur back august reorgan
oper busi thornal help holog
busi return growth europ work
stephen mcmillan day
close follow result cynosur next
quarter see manag restart growth especi
medic aesthet busi typic experi
tailwind holiday season given
turn around ail segment past particularli
intern segment continu forecast double-
digit growth cynosur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
